NCT01352338View on ClinicalTrials.gov

Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

February 29, 2016

Conditions
Multiple Myeloma
Interventions
DRUG

Lenalidomide, endoxan, prednisone

dose-finding

DRUG

lenalidomide, endoxan, prednisone

oral therapy with lenalidomide 25mg a day during 3 of 4 week cycles. Number of Cycles: until progression or unacceptable toxicity develops.

Trial Locations (3)

3435 CM

Antonius Ziekenhuis Nieuwegein, Nieuwegein

3584CX

UMC Utrecht, Utrecht

Unknown

VU Medical Center, Amsterdam

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

UMC Utrecht

OTHER

NCT01352338 - Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT) | Biotech Hunter | Biotech Hunter